After hosting two days of investors with management, Jefferies analyst David Steinberg believes Horizon Pharma's "strong" execution continues to transform its portfolio from primary care drugs to one largely comprised of rare disease assets. Pre-commercial activities are moving rapidly for the company's "large" new biologics opportunity with teprotumumab and a biologics license application filing is imminent, Steinberg tells investors in a research note. And while Horizon remains active in business development, management believes it sales can double in the coming years driven by Krystexxa and teprotumumab, the analyst adds. He keeps a Buy rating on Horizon Pharma with a $34 price target.